Sertraline in the Treatment of Depressive Disorders in Patients with Parkinson's Disease

Overview

Journal Neurol Sci

Specialty Neurology

Date 2008 Nov 13

PMID 19002650

Citations 5

Authors

Silvia Marino

Edoardo Sessa

Giuseppe Di Lorenzo

Giuseppina Digangi

Antonella Alagna

Placido Bramanti

Paolo Di Bella

Affiliations

Soon will be listed here.

Abstract

We studied 54 idiopathic Parkinson's disease (PD) patients with depressive disorders (DD) to compare the efficacy and the effect of treatment with sertraline in the usual formulation and in the liquid oral concentrate (LOC) formulation. After 6 months of sertraline treatment, the Hamilton Depression Rating Scale and the Montgomery and Asberg Depression Rating Scale showed a decrement (p<0.001, for both formulations). Parkinson's Disease Questionnaire scores improved (p<0.005 for usual formulation and p<0.001 for LOC formulation), as did Clinical Global Impression-Severity of Illness scale and Clinical Global Impression-Global Improvement scale scores (p=0.1, for both formulations). Mini Mental State Examination and Unified Parkinson's Disease Rating Scale motor subscores did not change. These results suggest that sertraline LOC may also be a useful treatment for DD in PD patients, especially for those with swallowing problems, and have significant benefit for quality of life, without worsening of parkinsonian features.

Citing Articles

Levodopa: From Biological Significance to Continuous Monitoring.

Probst D, Batchu K, Younce J, Sode K ACS Sens. 2024; 9(8):3828-3839.

PMID: 39047295 PMC: 11348912. DOI: 10.1021/acssensors.4c00602.

Mental Health Practitioners' Understanding of Speech Pathology in a Regional Australian Community.

Janes T, Signal T, Zupan B Healthcare (Basel). 2021; 9(11).

PMID: 34828531 PMC: 8622772. DOI: 10.3390/healthcare9111485.

Monoamine reuptake inhibitors in Parkinson's disease.

Huot P, Fox S, Brotchie J Parkinsons Dis. 2015; 2015:609428.

PMID: 25810948 PMC: 4355567. DOI: 10.1155/2015/609428.

Suppression of dynamin GTPase decreases α-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy.

Konno M, Hasegawa T, Baba T, Miura E, Sugeno N, Kikuchi A Mol Neurodegener. 2012; 7:38.

PMID: 22892036 PMC: 3479026. DOI: 10.1186/1750-1326-7-38.

Cortical serotonin and norepinephrine denervation in parkinsonism: preferential loss of the beaded serotonin innervation.

Nayyar T, Bubser M, Ferguson M, Neely M, Goodwin J, Montine T Eur J Neurosci. 2009; 30(2):207-16.

PMID: 19659923 PMC: 2765981. DOI: 10.1111/j.1460-9568.2009.06806.x.

References

Behari M, Srivastava A, Pandey R . Quality of life in patients with Parkinson's disease. Parkinsonism Relat Disord. 2005; 11(4):221-6. DOI: 10.1016/j.parkreldis.2004.12.005. View

Peto V, Jenkinson C, Fitzpatrick R . PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol. 1998; 245 Suppl 1:S10-4. DOI: 10.1007/pl00007730. View

Gelb D, Oliver E, Gilman S . Diagnostic criteria for Parkinson disease. Arch Neurol. 1999; 56(1):33-9. DOI: 10.1001/archneur.56.1.33. View

Hauser R, Zesiewicz T . Sertraline for the treatment of depression in Parkinson's disease. Mov Disord. 1997; 12(5):756-9. DOI: 10.1002/mds.870120522. View

Dooneief G, Mirabello E, Bell K, Marder K, Stern Y, Mayeux R . An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol. 1992; 49(3):305-7. DOI: 10.1001/archneur.1992.00530270125028. View

Brady K, Clary C . Affective and anxiety comorbidity in post-traumatic stress disorder treatment trials of sertraline. Compr Psychiatry. 2003; 44(5):360-9. DOI: 10.1016/S0010-440X(03)00111-1. View

Richard . Depression in Parkinson's Disease. Curr Treat Options Neurol. 2000; 2(3):263-274. DOI: 10.1007/s11940-000-0008-z. View

Gony M, Lapeyre-Mestre M, Montastruc J . Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs. Clin Neuropharmacol. 2003; 26(3):142-5. DOI: 10.1097/00002826-200305000-00007. View

Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani C, Pezzoli G . Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord. 2000; 15(5):986-9. DOI: 10.1002/1531-8257(200009)15:5<986::aid-mds1034>3.0.co;2-i. View

10.

Antonini A, Tesei S, Zecchinelli A, Barone P, De Gaspari D, Canesi M . Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. Mov Disord. 2006; 21(8):1119-22. DOI: 10.1002/mds.20895. View

11.

Sawabini K, Watts R . Treatment of depression in Parkinson's disease. Parkinsonism Relat Disord. 2004; 10 Suppl 1:S37-41. DOI: 10.1016/j.parkreldis.2004.02.002. View

12.

Davidson J . Pharmacotherapy of social phobia. Acta Psychiatr Scand Suppl. 2003; (417):65-71. DOI: 10.1034/j.1600-0447.108.s417.7.x. View

13.

Montgomery S, Asberg M . A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134:382-9. DOI: 10.1192/bjp.134.4.382. View

14.

Kuopio A, Marttila R, Helenius H, Toivonen M, Rinne U . The quality of life in Parkinson's disease. Mov Disord. 2000; 15(2):216-23. DOI: 10.1002/1531-8257(200003)15:2<216::aid-mds1003>3.0.co;2-#. View

15.

Rampello L, Chiechio S, Raffaele R, Vecchio I, Nicoletti F . The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa. Clin Neuropharmacol. 2002; 25(1):21-4. DOI: 10.1097/00002826-200201000-00004. View

16.

Goldstein B, Goodnick P . Selective serotonin reuptake inhibitors in the treatment of affective disorders--III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol. 1998; 12(3 Suppl B):S55-87. DOI: 10.1177/0269881198012003041. View

17.

Devanand D, Pelton G, Marston K, Camacho Y, Roose S, Stern Y . Sertraline treatment of elderly patients with depression and cognitive impairment. Int J Geriatr Psychiatry. 2003; 18(2):123-30. DOI: 10.1002/gps.802. View

18.

Erdal K . Depressive symptom patterns in patients with Parkinson's disease and other older adults. J Clin Psychol. 2001; 57(12):1559-69. DOI: 10.1002/jclp.1118. View

19.

Liebowitz M, DeMartinis N, Weihs K, Londborg P, Smith W, Chung H . Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry. 2003; 64(7):785-92. DOI: 10.4088/jcp.v64n0708. View

20.

McDonald W, Richard I, DeLong M . Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry. 2003; 54(3):363-75. DOI: 10.1016/s0006-3223(03)00530-4. View